Advanced bioprinting of perfusable human tissues depends on coordinated innovations across materials science, engineering, and cell biology. Clinical demand for transplantable tissues and drug-testing platforms drives research toward solutions that combine printable bioinks, vascular templating, and perfusable culture systems. Leaders in the field include Anthony Atala Wake Forest Institute for Regenerative Medicine for organ-scale constructs and Jennifer Lewis Harvard for multimaterial printing and sacrificial ink strategies, whose work illustrates how materials and hardware must align for scale.
Materials and printing strategies
Progress in bioinks has been critical: hybrid hydrogels that combine structural polymers with cell-adhesive and degradable components permit printing of mechanically robust yet cell-friendly matrices. Advances in sacrificial inks and fugitive materials allow creation of hollow channels that can be endothelialized to form functional vessels. Jordan Miller Rice University demonstrated approaches to generate hierarchical microvascular networks using dissolvable templates, while innovations in coaxial extrusion and embedded printing enable simultaneous deposition of lumen-forming materials and supporting parenchymal cell matrices. These approaches reduce collapse and improve channel fidelity but require careful matching of rheology and crosslinking kinetics to cell viability.
Biological integration and scaling
Engineering perfusion-ready tissues also requires reproducing native cues for vascularization. Endothelial cell sourcing and controlled delivery of angiogenic signals encourage integration between printed channels and host vasculature. Gordana Vunjak-Novakovic Columbia University has emphasized scalable bioreactor systems that provide physiological shear and oxygen gradients to mature thick tissues. On the manufacturing side, modular assembly and automated biofabrication platforms informed by computational design enable replication of repeatable units that can be perfused and matured in parallel. Robert Langer MIT has contributed foundational biomaterials and translational perspectives that underscore regulatory and manufacturing considerations for clinical-scale production.
Clinical, social, and environmental consequences follow: scalable vascularized tissues could reduce reliance on donor organs and accelerate personalized medicine, but equitable access and regulatory oversight must be addressed to prevent disparities. Energy and material demands of large-scale bioprinting raise environmental questions about sustainable biomaterials and lifecycle impacts. Balancing innovation with stewardship and equity will determine whether these technologies translate into broadly available therapies.